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Abstract  27 
Biofilm formation of multidrug and extensively drug resistant Klebsiella pneumoniae isolates is 28 
poorly understood.  We investigated 139 diverse clinical K. pneumoniae isolates that possess 29 
various resistance patterns to evaluate the relationship between biofilm formation and resistance.  30 
Antimicrobial resistance was compared among a diverse collection of weak versus strong biofilm-31 
forming K. pneumoniae, and predictors of strong biofilm formation were identified.  Multi-drug 32 
resistant isolates were more common among weak (97.9%) versus strong biofilm formers (76%; 33 
p=0.002).  Carbapenem-resistant K. pneumoniae were 91% less likely to form strong biofilm (odds 34 
ratio 0.09; 95% confidence interval 0.02-0.33). The statistically significant inverse relationship 35 
between biofilm formation and antibiotic resistance suggests that virulence may be a trade-off for 36 
survival.  37 
 38 
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INTRODUCTION 52 
Klebsiella pneumoniae, the most common and most concerning carbapenem-resistant 53 
Enterobacteriaceae (CRE) (1), is associated with mortality rates up to 50% (2).  Adding to this 54 
challenging infection is K. pneumoniae’s high propensity to form biofilms (3, 4).  Biofilm-forming 55 
K. pneumoniae are associated with foreign indwelling device related infections (4), as well as 56 
urinary stones (5-7).  The most common K. pneumoniae infections include urinary tract infections, 57 
pneumonia, as well as intra-abdominal infections, which are prone to biofilm formation(4, 8). 58 
Biofilm eradication requires high antimicrobial concentrations (9), which often cannot be 59 
physiologically achieved in the blood stream or at the site of infection, thus potentially leading to 60 
infection recurrence (4).  Unfortunately, clinical microbiology labs cannot routinely test for biofilm 61 
formation; however, tested phenotypic characteristics may help clinicians predict biofilm potential. 62 
 63 
Multidrug-resistant (MDR) organisms have been associated with biofilm formation when 64 
Klebsiella pneumoniae (10, 11), Staphylococcus aureus (11), Acinetobacter spp. (10, 11), 65 
Pseudomonas aeruginosa (10, 11), Escherichia coli (10, 11), coagulase-negative staphylococci 66 
(10), or Enterococcus spp. (10) are assessed together (10, 11).  However, the relationship 67 
between biofilm-forming K. pneumoniae alone and antimicrobial resistance has not been fully 68 
elucidated (12-14).  The study objective was to determine whether certain antimicrobial class 69 
resistance in K. pneumoniae was predictive of strong biofilm formation.   70 
 71 
MATERIALS AND METHODS: 72 
Our study included 139 unique K. pneumoniae clinical isolates obtained from the Centers for 73 
Disease Control and Prevention (CDC; n=66), Biodefense and Emerging Infections (BEI; n=36), 74 
American Type Culture Collection (ATCC; n=3), and Providence Veterans Affairs (VA) Medical 75 
Center and Rhode Island Hospital (n=34).  These isolates were selected because they are known 76 
to be resistant to a range of antibiotic classes.    Isolates from the Providence VA Medical Center 77 
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were collected per the VA approved Institutional Review Board (IRB), Research and Development 78 
(R&D), and safety committee protocols.  79 
A previously described biofilm assay was performed to assess biofilm formation (15-19).  This 80 
assay is considered the standard for evaluation of bacterial attachment and biofilm formation in 81 
vitro (20).  Isolates were obtained from culture stocks, stored at -80oC.  After streaking on tryptic 82 
soy agar and incubating for 18 to 24 hours, an inoculum of 6 log10 CFU/mL in tryptic soy broth 83 
with added 25 mg/L calcium, 12.5 mg/L magnesium, and 1.25% total dextrose (21).  Media was 84 
selected and validated based on the greatest biofilm formation, which is consistent with previously 85 
published data for Escherichia coli (22) and Klebsiella pneumoniae (17, 18).  Each isolate was 86 
incubated in a 96-well plate (Costar 3596) for 24 hours at 37oC and 120 rpm in octuplicate (17, 87 
18).  Wells were stained with 0.1% crystal violet (CV) and resolubilized with 33% glacial acetic 88 
acid (19).  K. pneumoniae (ATCC 700603) served as the biofilm positive control and media alone 89 
was the negative control (12, 23-25).   90 
Biofilm formation was measured as an optical density (OD570).  We further categorized isolates 91 
as either weak, moderate, or strong biofilm formers based on tertiles of OD570.  In order to assess 92 
differences between the highest and lowest OD570, we removed isolates in the moderate range 93 
(19, 26).   94 
Organism susceptibility was obtained from the site of collection (eg. CDC, BEI).  When results 95 
were unavailable testing was performed by E-test or Kirby-Bauer disc diffusion on Mueller-Hinton 96 
agar, and were interpreted according to 2017 CLSI susceptibility breakpoints (27, 28).  The FDA 97 
package insert for tigecycline (E-test MIC ≤2) (29) and EUCAST breakpoints for colistin (E-test 98 
MIC ≤2) and fosfomycin (E-test MIC ≤32 and disc diffusion ≥24; both contained glucose-6-99 
phosphate) (30) were used as CLSI breakpoints were not available.  Isolates were categorized 100 
as multi-drug resistant (MDR), extensively drug-resistant (XDR), or resistant to specific 101 
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antimicrobial classes/agents, according to CDC and European CDC expert consensus definitions 102 
for Enterobacteriaceae (31).  MDR isolates demonstrated non-susceptibility to at least one agent 103 
in three or more antimicrobial categories out of 16 antimicrobial categories and XDR isolates 104 
demonstrated susceptibility to at least one agent in less than or equal to two out of 16 antimicrobial 105 
categories (31).  106 
To assess the relationship between biofilm formation and resistance to specific antimicrobial 107 
classes/agents, we grouped the 16 antimicrobial categories into 12 categories based on 108 
mechanism of action (Table 1).  Piperacillin/tazobactam and penicillin/β-lactamase inhibitors were 109 
grouped as penicillins plus β-lactamase inhibitors, and non-extended spectrum cephalosporins, 110 
extended-spectrum cephalosporins, cephamycins, and ceftaroline were grouped as 111 
cephalosporins. This allowed us to avoid collinearity in our statistical models due to overlap in 112 
resistance between antimicrobial categories.   113 
Differences in antimicrobial resistance among the weak and strong biofilm formation groups were 114 
assessed with chi-square, Fisher’s exact, or t-test as appropriate.  Predictors of strong biofilm 115 
formation were identified from a logistic regression model.  A p-value of 0.1 was used for initial 116 
inclusion in the model (Table 1) and stepwise backward elimination was used to identify 117 
statistically significant predictors of strong biofilm formation (all p-values <0.05).  We assessed 118 
multicollinearity between potential predictors in the initial model from variance inflation factors, 119 
and confirmed the absence of collinearity.  A sensitivity analysis was conducted to identify 120 
predictors of biofilm formation as a continuous measure (OD570) using linear regression. 121 
 122 
RESULTS 123 
Optical density (OD570) for all 139 isolates were divided using tertiles as follows: weak (n=47; 124 
OD570 ≤ 0.16), moderate (n=46; 0.16 < OD570 < 0.59), and strong biofilm formers (n=46; OD570 ≥ 125 
0.59) (26).  This method was internally validated as the positive control was consistently 126 
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categorized as a strong biofilm former (OD570 ≥ 0.59) (26).  Moderate isolates were removed for 127 
a total cohort of 93 isolates (Table 1) to best predict biofilm formation extremes (26).   128 
 129 
MDR isolates (n=81) were more common among weak biofilm formers (n=46, 97.9%) versus 130 
strong biofilm formers (n=35, 76.1%; p=0.002), and XDR (n=25) isolates were similar between 131 
the groups (n=12, 25.5% vs. n=13, 28.3% p=0.77).  Number of resistant antimicrobial categories 132 
and OD570 are shown in Figure 1.  Resistance to all classes of beta-lactams (i.e. penicillins plus 133 
β-lactamase inhibitors, cephalosporins, monobactams, and carbapenems), aminoglycosides, 134 
chloramphenicol, and fluoroquinolones were more common among weak biofilm formers 135 
(p<0.05).  In the multivariate model, the only predictor of biofilm formation was carbapenem 136 
resistance, which was inversely associated with strong biofilm formation (odds ratio, OR 0.09; 137 
95% confidence interval, CI 0.02-0.33).  Therefore, carbapenem-resistant K. pneumoniae were 138 
91% less likely to form strong biofilm.   139 
 140 
As the proportion of XDR isolates did not vary between weak and strong biofilm formers, we 141 
conducted a post-hoc sensitivity subgroup analysis excluding XDR isolates (n=68) (Table 2).  142 
Predictors of strong biofilm formation were again identified from a stepwise backward elimination 143 
logistic regression model, with a p-value of 0.1 used for initial inclusion in the model (Table 2).  144 
The only predictor of strong biofilm formation was the number of resistant categories, with an 145 
odds ratio of 0.70 (95% CI 0.56-0.86), where the odds of strong biofilm formation decreased by 146 
30% with each increase in the number of resistant categories.  147 
 148 
In the sensitivity analysis of the continuous measure of biofilm formation, only fluoroquinolone 149 
resistance was predictive of the OD570, with a parameter estimate of -0.44 and an intercept of 0.86 150 
(p<0.001).  According to this model, fluoroquinolone susceptibility had an OD570 of 0.86, while 151 
fluoroquinolone resistance had an OD570 of 0.42.  In other words, fluoroquinolone susceptible 152 
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isolates were predicted to be strong biofilm formers, and fluoroquinolone resistant isolates were 153 
predicted to be moderate biofilm formers.   154 
 155 
DISCUSSION 156 
This is the first study to our knowledge, to identify a statistically significant inverse relationship 157 
between K. pneumoniae antimicrobial resistance and biofilm formation, where carbapenem-158 
resistant K. pneumoniae isolates were 91% less likely to be strong biofilm formers. Several 159 
published studies have described higher biofilm formation in resistant K. pneumoniae isolates, 160 
however, these descriptive studies did not assess whether resistance was predictive of  biofilm 161 
formation in multivariate analyses (10-14).  This is also the first study to assess resistance and 162 
biofilm formation of a diverse collection of K. pneumoniae isolates from multiple sources and 163 
centers.  Inclusion of isolates only from a single-center introduces potential bias if patients are 164 
infected with the same organism, especially if isolates are from an outbreak (14).  Additional 165 
rationale for the difference in findings requires further research.     166 
 167 
Potential limitations of our study include the overall resistance patterns of our isolates.  The 168 
majority of our isolates (n=81, 87.1%) were MDR, with the most isolates (n=64, 68.8%) resistant 169 
to at least 12 out of 16 antimicrobial classes, but only 26.9% (n=25) were XDR.  Inclusion of more 170 
susceptible or XDR isolates may have resulted in different predictors of biofilm formation. As a 171 
post-hoc sensitivity analysis we excluded XDR isolates, which support the findings from the weak 172 
versus strong analysis, where strong biofilm formation was 30% less likely with each increase in 173 
the number of resistant categories.  174 
 175 
Findings from previous studies may also be limited by misclassification of biofilm formation, which 176 
may affect conclusions that biofilm formation is more common among resistant isolates. The 177 
definition of biofilm formation varies across studies but the most common definition was originally 178 
8 
 
described for Staphylococcus spp. (15, 16).  This method utilizes an OD cut-off (ODc), defined as 179 
three standard deviations above the average OD of the negative control, to determine biofilm 180 
formation.  Isolates are either non-adherent (OD ≤ ODc), weakly adherent (ODc < OD ≤ 2xODc), 181 
moderately adherent (2xODc < OD ≤ 4xODc), or strongly adherent (4x ODc < OD).  182 
Categorization by this method however, is limited when the negative control has a negligible OD 183 
reading, which was the case for our study and previously described literature (12, 13).  Applying 184 
this method to our cohort, zero isolates were non-adherent, two weak, 12 moderate, and 125 185 
strong biofilm formers.  Therefore, we divided biofilm formation into tertiles (26), to overcome 186 
potential bias of overestimating strong biofilm formation (12).  Previous utilization of tertile biofilm 187 
categorization was also utilized for S. aureus, however categorization should not be affected by 188 
organism as our biofilm quantification method utilized was adapted for K. pneumoniae.  We also 189 
assessed biofilm formation as a continuous variable since there is no standard categorization.  190 
However, interpretation of resulting odds ratios is challenging when compared to a dichotomous 191 
variable of resistance versus susceptible, and is less clinically meaningful. 192 
 193 
Optical density remains an indirect measurement of biofilm formation and standardized methods 194 
for both quantification and categorization of K. pneumoniae biofilm formation are needed.  Varied 195 
definitions of biofilm formation are utilized, making direct comparisons across studies difficult.  It 196 
is imperative to standardize biofilm quantification to allow for accurate assessment of predictors 197 
of biofilm across settings and to quantify the relationship between biofilm forming isolates and 198 
clinical outcomes.   199 
 200 
In our study, strong biofilm formation was 91% less likely with carbapenem-resistant K. 201 
pneumoniae, which allows clinicians to better predict K. pneumoniae’s ability to produce biofilm 202 
by phenotypic resistance. This inverse relationship between biofilm formation and antibiotic 203 
resistance suggests that virulence may be a trade-off for bacterial survival.  204 
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Table 1. Klebsiella pneumoniae: antimicrobial resistance and biofilm formation 342 
Variable 
Total 
Cohort 
(n=93) 
Weak 
Biofilm 
Formation 
(n=47) 
Strong 
Biofilm 
Formation 
(n=46) 
p-value 
Number of Resistant Categories (n=16), 
Median, (IQR) 
13 (11-
14) 
13 (12-14) 11.5 (3-14) 0.01 
Multidrug-resistant (MDR), n (%)* 81 (87.1) 46 (97.9) 35 (76.1) 0.002 
Extensively drug-resistant (XDR), n (%)** 25 (26.9) 12 (25.5) 13 (28.3) 0.77 
Penicillins + β-lactamase inhibitors, n 
(%)ǂ 
79 (84.9) 46 (97.9) 33 (71.7) 0.0004 
Cephalosporins, n (%) 82 (88.2) 46 (97.9) 36 (78.3) 0.003 
Monobactam, n (%)  73 (78.5) 45 (95.7) 28 (60.9) <0.0001 
Carbapenems, n (%)ǂ ǂ 70 (75.3) 44 (93.6) 26 (56.5) <0.0001 
Aminoglycosides, n (%) 72 (77.4) 43 (91.5) 29 (63.0) 0.001 
Chloramphenicol, n (%) 65 (69.9) 38 (80.9) 27 (58.7) 0.02 
Fluoroquinolones, n (%) 73 (78.5) 45 (95.7) 28 (60.9) <0.0001 
Tigecycline, n (%) 13 (14.0) 6 (12.8) 7 (15.2) 0.73 
Tetracyclines, n (%) 44 (47.3) 23 (48.9) 21 (45.7) 0.75 
Folate pathway inhibitor, n (%) 66 (71.0) 37 (78.7) 29 (63.0) 0.09 
Fosfomycin, n (%) 61 (65.6) 29 (61.7) 32 (69.6) 0.42 
Colistin, n (%) 11 (11.8) 8 (17.0) 3 (6.5) 0.12 
Bolded p-values indicate potential predictors of strong biofilm formation included in the initial 343 
logistic regression model 344 
16 
 
*MDR isolates demonstrated non-susceptibility to at least one agent in three or more 345 
antimicrobial categories out of 16 antimicrobial categories  346 
**XDR isolates demonstrated susceptibility to at least one agent in less than or equal to two out 347 
of 16 antimicrobial categories 348 
ǂpenicillin + β-lactamase inhibitors category includes piperacillin/tazobactam and penicillin/ β-349 
lactamase inhibitors 350 
ǂ ǂcephalosporins category includes non-extended spectrum cephalosporins, extended-351 
spectrum cephalosporins, cephamycins, and ceftaroline 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
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Table 2. Sensitivity analysis of non-XDR Klebsiella pneumoniae: antimicrobial 368 
resistance and biofilm formation 369 
Variable 
Total 
Cohort 
(n=68) 
Weak 
Biofilm 
Formation 
(n=35) 
Strong 
Biofilm 
Formation 
(n=33) 
p-value 
Number of Resistant Categories (n=16), 
Median, (IQR)  
12 (8-13) 13 (12-13) 9 (1-12) <0.0001 
Multidrug-resistant (MDR), n (%)* 56 (82.4) 34 (97.1) 22 (66.7) 0.001 
Extensively drug-resistant (XDR), n (%)** 0 0 0 --- 
Penicillins + β-lactamase inhibitors, n (%) 54 (79.4) 34 (97.1) 20 (60.6) 0.0002 
Cephalosporins, n (%) 57 (83.8) 34 (97.1) 23 (69.7) 0.002 
Monobactam, n (%)  48 (70.6) 33 (94.3) 15 (45.5) <0.0001 
Carbapenems, n (%) 45 (66.2) 32 (91.4) 13 (39.4) <0.0001 
Aminoglycosides, n (%) 48 (70.6) 32 (91.4) 16 (48.5) 0.001 
Chloramphenicol, n (%) 40 (58.8) 26 (74.3) 14 (42.4) 0.008 
Fluoroquinolones, n (%) 48 (70.6) 33 (94.3) 15 (45.5) <0.001 
Tigecycline, n (%) 6 (8.8) 4 (11.4) 2 (6.1) 0.67 
Tetracyclines, n (%) 20 (29.4) 12 (34.3) 8 (24.2) 0.36 
Folate pathway inhibitor, n (%) 41 (60.3) 25 (71.4) 16 (48.5) 0.053 
Fosfomycin, n (%) 41 (60.3) 19 (54.3) 22 (66.7) 0.30 
Colistin, n (%) 6 (8.8) 4 (11.4) 2 (6.1) 0.44 
Bolded p-values indicate potential predictors of strong biofilm formation included in the initial 370 
logistic regression model 371 
18 
 
*MDR isolates demonstrated non-susceptibility to at least one agent in three or more 372 
antimicrobial categories out of 16 antimicrobial categories  373 
**XDR isolates demonstrated susceptibility to at least one agent in less than or equal to two out 374 
of 16 antimicrobial categories 375 
ǂpenicillin + β-lactamase inhibitors category includes piperacillin/tazobactam and penicillin/ β-376 
lactamase inhibitors 377 
ǂ ǂcephalosporins category includes non-extended spectrum cephalosporins, extended-378 
spectrum cephalosporins, cephamycins, and ceftaroline 379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
 387 
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